Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 11:25AM ET
60.94
Dollar change
+0.44
Percentage change
0.72
%
IndexRUT P/E- EPS (ttm)-3.50 Insider Own49.04% Shs Outstand17.40M Perf Week-0.76%
Market Cap1.50B Forward P/E- EPS next Y-5.29 Insider Trans-12.99% Shs Float12.58M Perf Month-6.44%
Income-76.43M PEG- EPS next Q-1.02 Inst Own51.88% Short Float10.05% Perf Quarter5.20%
Sales0.00M P/S- EPS this Y-26.97% Inst Trans4.20% Short Ratio4.33 Perf Half Y25.76%
Book/sh14.87 P/B4.10 EPS next Y-21.70% ROA-26.90% Short Interest1.26M Perf Year176.65%
Cash/sh14.60 P/C4.17 EPS next 5Y- ROE-29.30% 52W Range18.25 - 77.60 Perf YTD5.51%
Dividend Est.- P/FCF- EPS past 5Y- ROI-21.20% 52W High-21.46% Beta0.17
Dividend TTM- Quick Ratio25.96 Sales past 5Y0.00% Gross Margin- 52W Low233.95% ATR (14)3.67
Dividend Ex-Date- Current Ratio17.06 EPS Y/Y TTM50.94% Oper. Margin0.00% RSI (14)43.49 Volatility6.74% 6.67%
Employees46 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.22 Target Price81.33
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q19.77% Payout- Rel Volume0.26 Prev Close60.51
Sales Surprise- EPS Surprise-16.70% Sales Q/Q- EarningsMar 21 BMO Avg Volume292.16K Price60.94
SMA20-6.35% SMA50-7.01% SMA20011.08% Trades Volume25,228 Change0.72%
Date Action Analyst Rating Change Price Target Change
Dec-19-23Downgrade Morgan Stanley Overweight → Equal-Weight $56 → $65
Jun-09-23Upgrade Raymond James Outperform → Strong Buy $50 → $75
Jun-07-23Initiated H.C. Wainwright Buy $55
May-17-23Initiated Raymond James Outperform $50
Apr-28-23Initiated Cantor Fitzgerald Overweight $45
Apr-21-23Initiated Stifel Buy $37
Apr-20-23Initiated Morgan Stanley Overweight $37
Mar-23-23Initiated BMO Capital Markets Outperform $40
Feb-28-23Initiated SVB Securities Outperform $36
Mar-23-24 05:31AM
Mar-21-24 08:00AM
Mar-06-24 04:30PM
Feb-26-24 08:30AM
Feb-20-24 08:30AM
09:00AM Loading…
Feb-09-24 09:00AM
Feb-07-24 08:00AM
Jan-03-24 05:00PM
Dec-22-23 06:35PM
Dec-20-23 04:30PM
Dec-15-23 03:01PM
Dec-11-23 08:30PM
12:00PM
Dec-08-23 07:06AM
Nov-14-23 04:44PM
09:55AM Loading…
Nov-13-23 09:55AM
Nov-09-23 09:34AM
08:30AM
Nov-08-23 04:30PM
Nov-02-23 09:00AM
Oct-23-23 09:15AM
Oct-03-23 08:30AM
Sep-20-23 04:30PM
Aug-30-23 04:15PM
Aug-24-23 11:20AM
Aug-11-23 08:50AM
08:00AM
Jul-27-23 09:00AM
Jul-25-23 09:55AM
Jun-22-23 04:15PM
07:33PM Loading…
Jun-20-23 07:33PM
Jun-13-23 10:39PM
Jun-12-23 04:00PM
01:59AM
Jun-09-23 04:13PM
07:00AM
Jun-01-23 03:10PM
May-31-23 04:00PM
May-15-23 07:00AM
May-11-23 10:15AM
May-10-23 10:23AM
May-05-23 08:50AM
May-04-23 12:00PM
Apr-28-23 05:00AM
Apr-27-23 08:05AM
Apr-21-23 08:30AM
Apr-19-23 08:50AM
Apr-13-23 11:00AM
Mar-31-23 07:00AM
Mar-30-23 07:05AM
Mar-21-23 07:00AM
Feb-16-23 08:00AM
Feb-14-23 06:30AM
Feb-08-23 04:00PM
Jan-20-23 07:00AM
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel treatments for hematologic disorders. Its programs include Bitopertin, DISC-0974, and DISC-3405. The company was founded in October 2017 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bitterman KevinDirectorMar 05 '24Sale73.5026,1571,922,540677,503Mar 07 04:40 PM
Bitterman KevinDirectorJan 23 '24Sale67.65102,5006,934,125198,326Jan 25 04:33 PM
Atlas Venture Fund X, L.P.10% OwnerJan 23 '24Sale67.65102,5006,934,125198,326Jan 25 04:31 PM
Atlas Venture Fund X, L.P.10% OwnerJan 23 '24Sale67.6547,5003,213,3751,402,186Jan 25 04:31 PM
Atlas Venture Fund X, L.P.10% OwnerJan 10 '24Sale64.0030,0001,920,0001,449,686Jan 12 05:12 PM
Bitterman KevinDirectorJan 10 '24Sale64.0020,0001,280,000786,160Jan 12 05:12 PM
Atlas Venture Fund X, L.P.10% OwnerJan 10 '24Sale64.0020,0001,280,000786,160Jan 12 05:12 PM
Quisel John DChief Executive OfficerDec 29 '23Option Exercise1.012,7002,7272,700Jan 03 04:05 PM
Bryce JoanneChief Financial OfficerDec 27 '23Option Exercise9.863,00029,5805,500Dec 29 04:15 PM
Ashiya MonaDirectorDec 18 '23Option Exercise38.001,72465,5121,724Dec 20 06:16 PM
ORBIMED ADVISORS LLCDirectorDec 18 '23Option Exercise38.001,72465,5121,724Dec 20 06:28 PM
Ashiya MonaDirectorDec 18 '23Sale59.241,724102,1300Dec 20 06:16 PM
ORBIMED ADVISORS LLCDirectorDec 18 '23Sale59.241,724102,1300Dec 20 06:28 PM
ORBIMED ADVISORS LLCDirectorDec 14 '23Sale56.75433,20024,584,100224,405Dec 15 06:04 PM
Ashiya MonaDirectorDec 14 '23Sale56.75433,20024,584,100224,405Dec 15 06:09 PM
Atlas Venture Fund X, L.P.10% OwnerDec 14 '23Sale58.2830,8251,796,4371,479,686Dec 14 08:13 PM
Atlas Venture Fund X, L.P.10% OwnerDec 14 '23Sale58.2820,5491,197,567806,160Dec 14 08:13 PM
Bitterman KevinDirectorDec 14 '23Sale58.2820,5491,197,567806,160Dec 14 08:14 PM
ORBIMED ADVISORS LLCDirectorDec 14 '23Sale57.7320011,546727,807Dec 14 05:44 PM
Ashiya MonaDirectorDec 14 '23Sale57.7320011,546727,807Dec 14 05:40 PM
Ashiya MonaDirectorDec 13 '23Sale58.56106,7006,248,352281,505Dec 14 05:40 PM
ORBIMED ADVISORS LLCDirectorDec 13 '23Sale58.56106,7006,248,352281,505Dec 14 05:44 PM
Atlas Venture Fund X, L.P.10% OwnerDec 13 '23Sale60.005,323319,3571,510,511Dec 14 08:13 PM
Bitterman KevinDirectorDec 13 '23Sale60.003,548212,865826,709Dec 14 08:14 PM
Atlas Venture Fund X, L.P.10% OwnerDec 13 '23Sale60.003,548212,865826,709Dec 14 08:13 PM
White William RichardDirectorDec 12 '23Option Exercise6.0833,511203,88333,511Dec 14 04:15 PM
Bryce JoanneChief Financial OfficerDec 12 '23Option Exercise2.652,5006,6255,000Dec 14 04:15 PM
Atlas Venture Fund X, L.P.10% OwnerDec 12 '23Sale62.8077,9514,895,0321,515,834Dec 14 08:13 PM
Atlas Venture Fund X, L.P.10% OwnerDec 12 '23Sale62.8051,9673,263,328830,257Dec 14 08:13 PM
Bitterman KevinDirectorDec 12 '23Sale62.8051,9673,263,328830,257Dec 14 08:14 PM
White William RichardDirectorDec 12 '23Sale63.2133,5112,118,2390Dec 14 04:15 PM
ORBIMED ADVISORS LLCDirectorDec 12 '23Sale60.1627,3001,642,368295,605Dec 14 05:44 PM
Ashiya MonaDirectorDec 12 '23Sale60.1627,3001,642,368295,605Dec 14 05:40 PM
Bryce JoanneChief Financial OfficerDec 12 '23Sale65.222,500163,0622,500Dec 14 04:15 PM
Bryce JoanneChief Financial OfficerDec 05 '23Option Exercise1.011,2811,2945,041Dec 07 04:15 PM
Bryce JoanneChief Financial OfficerDec 05 '23Sale56.002,541142,2992,500Dec 07 04:15 PM
Khara RahulGeneral CounselNov 22 '23Option Exercise14.6910,000146,90010,000Nov 27 04:15 PM
Khara RahulGeneral CounselNov 22 '23Sale51.7310,000517,3330Nov 27 04:15 PM
Khara RahulGeneral CounselNov 14 '23Option Exercise14.694,90071,9814,900Nov 15 05:00 PM
Khara RahulGeneral CounselNov 14 '23Sale50.614,900248,0120Nov 15 05:00 PM
Khara RahulGeneral CounselNov 03 '23Option Exercise14.691001,469100Nov 07 06:22 PM
Khara RahulGeneral CounselNov 03 '23Sale50.001005,0000Nov 07 06:22 PM
Atlas Venture Fund X, L.P.10% OwnerSep 16 '23Sale53.222,115112,5601,593,785Sep 18 04:59 PM
Atlas Venture Fund X, L.P.10% OwnerSep 15 '23Sale53.16260,89413,869,1251,595,900Sep 18 04:59 PM
Atlas Venture Fund X, L.P.10% OwnerSep 14 '23Sale53.0594,4405,010,0421,856,794Sep 18 04:59 PM
Bryce JoanneChief Financial OfficerSep 11 '23Option Exercise9.862,50024,6503,760Sep 13 04:15 PM
Bryce JoanneChief Financial OfficerSep 01 '23Option Exercise2.651,0002,6502,260Sep 05 04:16 PM
Bryce JoanneChief Financial OfficerSep 01 '23Sale52.991,00052,9901,260Sep 05 04:16 PM
Savage William JacobChief Medical OfficerAug 21 '23Option Exercise2.653,0007,9503,000Aug 22 04:06 PM
Atlas Venture Fund X, L.P.10% OwnerAug 15 '23Sale52.40111,0695,820,0161,951,234Aug 16 06:55 PM
Bitterman KevinDirectorAug 15 '23Sale52.4072,9313,821,584882,224Aug 17 04:13 PM
Atlas Venture Fund X, L.P.10% OwnerAug 15 '23Sale52.4072,9313,821,584882,224Aug 16 06:55 PM
Savage William JacobChief Medical OfficerAug 15 '23Sale52.957,672406,2350Aug 16 04:15 PM
Atlas Venture Fund X, L.P.10% OwnerAug 14 '23Sale52.59175,0009,203,6002,062,303Aug 16 06:55 PM
Savage William JacobChief Medical OfficerAug 09 '23Sale49.838,269412,0647,672Aug 11 04:15 PM
Bryce JoanneChief Financial OfficerAug 01 '23Option Exercise1.014,5214,5665,781Aug 03 04:18 PM
Bryce JoanneChief Financial OfficerAug 01 '23Sale49.914,521225,6331,260Aug 03 04:18 PM
MacDonald Brian RichardChief Innovation OfficerJun 30 '23Sale45.054,324194,77812,876Jun 30 06:29 PM
MacDonald Brian RichardChief Innovation OfficerJun 29 '23Sale45.795,100233,50917,200Jun 30 06:29 PM
Bryce JoanneChief Financial OfficerJun 28 '23Option Exercise1.017,8807,95911,332Jun 30 04:49 PM
Novo Holdings A/S10% OwnerJun 28 '23Sale46.101,250,00057,625,0001,090,772Jun 28 05:04 PM
Bryce JoanneChief Financial OfficerJun 28 '23Sale49.9510,072503,1141,260Jun 30 04:49 PM
MacDonald Brian RichardChief Innovation OfficerJun 28 '23Sale49.965,100254,79522,300Jun 30 06:29 PM
Savage William JacobChief Medical OfficerJun 28 '23Sale49.984,384219,11415,941Jun 30 04:12 PM